CTX112 Trial
Phase 1/2
120
about 7 years
18+
4 sites in KS, MO, TX +1
What this study is about
This trial is testing the safety and effectiveness of CTX112 in people with relapsed or refractory B-cell malignancies. CTX112 is a type of immunotherapy that uses modified T cells to target cancer cells.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive CTX112
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1 (Dose Escalation): Incidence of adverse events, defined as dose-limiting toxicities, Phase 2 (Cohort Expansion): Objective response rate
Secondary: Duration of Response, Overall Survival, Progression Free Survival
Oncology